Seborrhea - Pipeline Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape.

PUNE, INDIA, September 26, 2016 /EINPresswire.com/ -- Seborrhea - Pipeline Review, H2 2016

Summary

‘Seborrhea - Pipeline Review, H2 2016’, provides an overview of the Seborrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seborrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seborrhea and features dormant and discontinued projects.

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

View More About this Report @ https://www.wiseguyreports.com/reports/649779-trigeminal-neuralgia-pipeline-review-h2-2016

Scope

- The report provides a snapshot of the global therapeutic landscape of Seborrhea
- The report reviews pipeline therapeutics for Seborrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seborrhea therapeutics and enlists all their major and minor projects
- The report assesses Seborrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seborrhea

Learn from Sample Report @ https://www.wiseguyreports.com/sample-request/649779-trigeminal-neuralgia-pipeline-review-h2-2016

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seborrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seborrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Enquiry before Buying this Report @ https://www.wiseguyreports.com/enquiry/649779-trigeminal-neuralgia-pipeline-review-h2-2016

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Seborrhea Overview 7
Therapeutics Development 8
Pipeline Products for Seborrhea - Overview 8
Pipeline Products for Seborrhea - Comparative Analysis 9
Seborrhea - Therapeutics under Development by Companies 10
Seborrhea - Therapeutics under Investigation by Universities/Institutes 11
Seborrhea - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Seborrhea - Products under Development by Companies 15
Seborrhea - Products under Investigation by Universities/Institutes 16
Seborrhea - Companies Involved in Therapeutics Development 17
Allergan Plc 17
Biogen Inc 18
KPI Therapeutics, Inc. 19
Merz Pharma GmbH & Co. KgaA 20
Trigemina, Inc. 21
Seborrhea - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
incobotulinumtoxin A - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
NeuroRelease TN - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
onabotulinumtoxin A - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
oxytocin - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
raxatrigine hydrochloride - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Seborrhea - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
U-2902 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Seborrhea - Dormant Projects 51

…continued

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649779

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here